Skip to main navigation
Neoleukin Therapeutics

Investors

Press Releases

Press Releases

Date Title View
January 8, 2021 Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
January 7, 2021 Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference

Investor Tools

  • Investor FAQs
  • Contact IR
  • Email Alerts

Neoleukin - Investors Menu (Secondary)

  • Press Releases
  • Events & Presentations
  • Financial and Filings
  • Stock Information
  • Analysts
  • Corporate Governance

Neoleukin - Investor Relations

  • About
    • Vision
    • Leadership
    • Board of Directors
    • Contact
  • Science
    • De Novo Protein Design
    • Neoleukin Platform
    • Publications
    • Collaborations & Partnerships
  • Programs
    • NL-201
    • Research
  • News
    • Press Releases
    • Events
    • In The News
    • Media Contact
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial and Filings
    • Stock Information
    • Analysts
    • Corporate Governance
    • Investor FAQs
    • Contact IR
    • Email Alerts
  • Careers
    • Overview
    • Job Opportunities
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Twitter
  • Neoleukin TherapeuticsHome
  • Neoleukin - Investor Relations

  • About
    • Vision
    • Leadership
    • Board of Directors
    • Contact
  • Science
    • De Novo Protein Design
    • Neoleukin Platform
    • Publications
    • Collaborations & Partnerships
  • Programs
    • NL-201
    • Research
  • News
    • Press Releases
    • Events
    • In The News
    • Media Contact
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial and Filings
    • Stock Information
    • Analysts
    • Corporate Governance
    • Investor FAQs
    • Contact IR
    • Email Alerts
  • Careers
    • Overview
    • Job Opportunities
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Twitter
©  Neoleukin Therapeutics, Inc. All rights reserved.
  • Twitter
  • Privacy Policy
  • Terms & Conditions